Effect of zoledronic acid in patients with renal cell cancer and bone metastasis.

Trial Profile

Effect of zoledronic acid in patients with renal cell cancer and bone metastasis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Renal cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Oct 2012 New source identified and integrated (German Clinical Trials Register DRKS00004119).
    • 26 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top